menu
    • menu
    [{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Mycovia Pharmaceuticals

    Menu

    Mycovia Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Jiangsu Hengrui Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Approval of Oteseco...

                            Details : VIVJOA® (oteseconazole) is an azole antifungal and designed to selectively inhibit fungal CYP51, which is indicated for the treatment of severe vulvovaginal candidiasis (VVC).

                            Product Name : Vivjoa

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 21, 2023

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Jiangsu Hengrui Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mycovia Pharmaceuticals’ Phase 3 ultraVIOLET Study Evaluating the Efficacy and Safety of VIVJOA™ (otesecon...

                            Details : VIVJOA (oteseconazole) was statistically superior to placebo in preventing recurrence of infection in women with RVVC and noninferior to fluconazole in treating acute VVC in women with RVVC.

                            Product Name : Vivjoa

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 25, 2022

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mycovia Pharmaceuticals Announces Publication of Positive Phase 3 Data Evaluating VIVJOA™ (oteseconazole) Ca...

                            Details : Two global VIOLET Phase 3 studies met primary and key secondary endpoints, with authors concluding VIVJOA (oteseconazole) is highly efficacious in preventing recurrence of VVC through 48 weeks in participants with a history of RVVC.

                            Product Name : Vivjoa

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 26, 2022

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA™ (oteseconazole) Capsules, the First and Only ...

                            Details : VIVJOA™ (oteseconazole) capsules are an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.

                            Product Name : Vivjoa

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 18, 2022

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mycovia Pharmaceuticals Announces Positive New Clinical Findings Evaluating VIVJOA™ (oteseconazole) Capsules...

                            Details : 85% of patients who took a 12-week course of Vivjoa (oteseconazole) completed 96 weeks without a recurrent VVC episode, with an average time of 92 weeks without recurrence.

                            Product Name : Vivjoa

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 22, 2022

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves Mycovia Pharmaceuticals’ VIVJOA™ (oteseconazole), the First and Only FDA-Approved Medication ...

                            Details : Approval of VIVJOA™ marks a significant therapeutic advancement for reducing the incidence of RVVC, a condition with substantial unmet need, in permanently infertile and postmenopausal women.

                            Product Name : Vivjoa

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 28, 2022

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mycovia Pharmaceuticals Announces Presentation of Topline Results from Two Studies Evaluating VIVJOA™ (otese...

                            Details : Of the 71 VIVJOA (oteseconazole) treated participants in the observational extension study, 85% completed 96 weeks without a recurrent VVC episode, where they had experienced at least three episodes in the year prior to study entry.

                            Product Name : Vivjoa

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 08, 2022

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mycovia Pharmaceuticals Announces Presentations of its Supportive Phase 3 Clinical Study (ultraVIOLET) Evaluat...

                            Details : Oteseconazole (VT-1161) is a novel, oral therapy for RVVC that is designed with the goal of having greater selectivity, fewer side effects and improved efficacy for treatment of recurrent vulvovaginal candidiasis (RVVC).

                            Product Name : Vivjoa

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 29, 2021

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mycovia Pharmaceuticals Announces Positive Topline Results from its Third Phase 3 Clinical Trial of Oteseconaz...

                            Details : The objective of the ultraVIOLET study was to assess the effectiveness of oteseconazole over 50 weeks in the prevention of recurring acute VVC episodes in women with a history of RVVC. The ultraVIOLET study met all primary and secondary endpoints.

                            Product Name : Vivjoa

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 01, 2021

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mycovia Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mycovia Pharmaceuticals Submits NDA to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovagi...

                            Details : Oteseconazole was designed to be highly selective for its pathogenic target, with fewer side effects and improved efficacy over current treatment options, including fluconazole, the current standard of care for vulvovaginal candidiasis (VVC).

                            Product Name : Vivjoa

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 06, 2021

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth